Baseline quality of life and chemotherapy toxicities in patients with early breast cancer

被引：4

作者：

Licaj, Idlir ^{[1
,2
]}

Coquan, Elodie ^{[1
,3
]}

Dabakuyo-Yonli, Tienhan Sandrine ^{[4
]}

Dauchy, Sarah ^{[5
]}

Vaz Luis, Ines ^{[6
]}

Charles, Cecile ^{[5
]}

Lemogne, Cedric ^{[7
]}

Tredan, Olivier ^{[8
]}

Vanlemmens, Laurence ^{[9
]}

Jouannaud, Christelle ^{[10
]}

Levy, Christelle ^{[11
]}

Rigal, Olivier ^{[12
]}

Fournier, Marion ^{[13
]}

Petit, Thierry ^{[14
]}

Dalenc, Florence ^{[15
]}

Rouanet, Philippe ^{[16
]}

Lemonnier, Jerome ^{[17
]}

Everhard, Sibille ^{[17
]}

Cottu, Paul ^{[18
]}

Joly, Florence ^{[1
,19
,20
]}

机构：

[1] Ctr Francois Baclesse, Clin Res Dept, Caen, France

[2] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway

[3] Ctr Francois Baclesse, Med Oncol, Caen, France

[4] Georges Francois Leclerc Canc Ctr UNICANCER, Breast & Gynecol Canc Registry Cote Or, Caen, France

[5] Gustave Roussy, Support Care Dept, Villejuif, France

[6] Med Oncol Gustave Roussy, Villejuif, France

[7] Hop Europeen Georges Pompidou, AP HP, Psychiat Dept, Paris, France

[8] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[9] Ctr Oscar Lambret, Dept Senol, Lille, France

[10] Inst Jean Godinot, Dept Med Oncol, 3 Ave Gen Harris, F-14000 Reims, France

[11] Ctr Francois Baclesse, Dept Clin Res Unit & Med Oncol, Caen, France

[12] Ctr Henri Becquerel, Dept Med Oncol, Rouen, France

[13] Inst Bergonie, Dept Surg Oncol, Bordeaux, France

[14] Ctr Paul Strauss, Dept Med Oncol, Strasbourg, France

[15] Inst Claudius Regaud, Dept Med Oncol, Toulouse, France

[16] Inst Canc Montpellier, Dept Surg, Montpellier, France

[17] UNICANCER, Res & Dev, Paris, France

[18] Inst Curie, Dept Med Oncol, Paris, France

[19] Univ Caen Normandie, Inst Natl St & Rech Med, ANTICIPE Unit, Caen, France

[20] Ligue Natl Canc, Canc & Cognit Platform, Caen, France

来源：

CANCER | 2023年 / 129卷 / 07期

关键词：

breast cancer; chemotherapy; patient-reported outcome; quality of life; toxicities; REPORTED OUTCOMES; PROGNOSTIC-FACTORS; CLINICAL-PRACTICE; RISK-FACTORS; FATIGUE; SURVIVAL; POPULATION; PREVALENCE; GUIDELINES; IMPACT;

D O I：

10.1002/cncr.34643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe authors used the French breast cancer Cancer and Toxicities (CANTO) cohort to study the associations between baseline quality of life and chemotherapy dose-reductions (CDRs) or postchemotherapy-toxicities (PCTs). MethodsIn total, 3079 patients with breast cancer who received chemotherapy were included in this analysis. The associations between baseline physical functioning (PF) and fatigue measured using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30, and two endpoints-CDRs during adjuvant or neoadjuvant chemotherapy; and selected PCTs were estimated with odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) using logistic regression models. ResultsAmong the 3079 patients from the CANTO cohort who were included, 718 (33.0%) received chemotherapy in the neoadjuvant setting, and 2361 (67.0%) received chemotherapy as adjuvant treatment. The chemotherapy included taxanes in 94.2% of patients and anthracyclines in 90.5% of patients. Overall, 15.5% of patients experienced CDRs and, 31.0% developed PCTs. Women with low baseline PF scores (<83) had higher multivariate odds of developing CDRs compared with those who had PF scores >= 83 (OR, 1.54; 95% CI, 1.13-2.09). The corresponding OR for PCTs was 1.50 (95% CI, 1.13-2.00). Women with high baseline fatigue scores had higher odds of CDRs (OR, 1.43; 95% CI, 1.13-1.76) and PCTs (OR, 1.32; 95% CI, 1.10-1.59). ConclusionsBy using the national CANTO cohort, baseline PF and fatigue were independently associated with CDRs and PCTs.

引用

页码：1085 / 1095

页数：11

共 53 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].